Content Conference Coverage Conferences IAS 2015
IAS 2015: START Supports ART For All [VIDEO]
- Details
- Category: HIV Treatment
- Created on Wednesday, 05 August 2015 00:00
Full results from the Strategic Timing of Antiretroviral Treatment (START) trial provide definitive evidence that starting antiretroviral therapy (ART) soon after HIV diagnosis, rather than waiting until the CD4 T-cell count falls below 500 cells/mm3, significantly reduces the risk of AIDS-related and non-AIDS illness and death, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.
IAS 2015: Same-day Antiretroviral Treatment Leads to Faster HIV Suppression in San Francisco
- Details
- Category: HIV Treatment
- Created on Thursday, 23 July 2015 00:00
A program at San Francisco General Hospital (SFGH) that offers antiretroviral therapy (ART) on the same day as HIV diagnosis led to a high rate of treatment uptake and more rapid viral load suppression than standard practices, according to late-breaking study findings presented at the 8th International AIDS Society Conference this week in Vancouver. Newly diagnosed people with HIV and clinic providers both expressed enthusiasm about the RAPID program, which is now being implemented more widely as part of the city's Getting to Zero initiative.
Coverage of the 2015 International AIDS Society Conference
- Details
- Category: HIV Treatment
- Created on Monday, 06 July 2015 00:00
HIVandHepatitis.com coverage of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), July 19-22, in Vancouver, Canada.
Conference highlights include HIV treatment as prevention, pre-exposure prophylaxis (PrEP), new antiretroviral therapies, HIV cure research, hepatitis C and HIV/HCV coinfection, and global scale-up of prevention and treatment.
7/22/15
IAS 2015: A New Era of HIV Treatment and Prevention [VIDEO]
- Details
- Category: HIV Treatment
- Created on Sunday, 19 July 2015 00:00
Nearly 20 years after the last major AIDS conference in Vancouver ushered in the era of life-saving antiretroviral therapy, we are now embarking on a new era of HIV treatment and prevention. "Vancouver is going to make history again -- treatment as prevention will be definitively established as the new standard of care," said conference co-chair Julio Montaner, kicking off the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015).
IAS 2015: Rilpivirine + Darunavir HIV Maintenance Regimen Matches Standard 3-Drug ART
- Details
- Category: Approved HIV Drugs
- Created on Tuesday, 08 September 2015 00:00
A NRTI-sparing dual antiretroviral regimen consisting of the NNRTI rilpivirine (Edurant) plus the boosted HIV protease inhibitor darunavir (Prezista) maintained viral suppression and was well-tolerated by people who switched from a standard 3-drug regimen, according to results from the PROBE study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
More Articles...
- IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV
- IAS 2015: Switching to Tenofovir Alafenamide Keeps HIV Suppressed, Helps Kidneys and Bones
- IAS 2015: New NNRTI Doravirine Suppresses HIV as Well as Efavirenz But with Fewer CNS Side Effects
- IAS 2015: Maturation Inhibitor BMS-955176 Shows Good Antiviral Activity with Atazanavir
- IAS 2015: START Trial Provides Definitive Evidence of Benefits of Early HIV Treatment
- IAS 2015: World Health Organization to Recommend HIV Treatment for All
- IAS 2015: Estrogen May Block HIV Reactivation, Hints at Gender Differences in Viral Reservoirs
- IAS 2015: Broadly Neutralizing Antibodies Against HIV [VIDEO]
- IAS 2015: Altered Cholesterol Metabolism May Protect Immune Cells of Non-Progressors
- IAS 2015: Zinc Finger Nuclease Genome Editing [VIDEO]
- IAS 2015: Targets Proliferate in HIV Cure Research
- IAS 2015: Young Woman Stays Undetectable for 12 Years Off Treatment After Early HIV Therapy
- IAS 2015: HIV+ Youth Are Less Likely than Adults to Achieve Viral Suppression on ART
- IAS 2015: Innovative Linkage to Care Approaches Boost Clinic Visits, HIV Treatment Uptake in African Study
- IAS 2015: Treatment Cascades Show 90-90-90 Goals Reachable, Eastern Europe Lags Behind Africa
- IAS 2015: Test and Treat Studies and African Country Experience Show 90-90-90 Targets Are Achievable
- IAS 2015: A Community Perspective on HIV Prevention Science [VIDEO]
- IAS 2015: Cash to Stay in School Didn't Reduce HIV Incidence, but Attendance Protects Young Women
- Half of U.S. Gay Men Using Dating Apps Have Interacted with a PrEP User
- IAS 2015: Information about HIV Treatment as Prevention Lessens Stigma and Increases Testing
- IAS 2015: No HIV Infections from Partners with Fully Suppressed Virus in Landmark Trial
- IAS 2015: Opioid Substitution Therapy Combined with HIV Treatment Saves More Lives
- IAS 2015: PrEP Adherence, Sexual Behavior, and HIV and STI Incidence [VIDEO]
- IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]
- IAS 2015: First Brazilian Data Reinforce Evidence that PrEP is Mostly Used by Those at Greatest Risk
- IAS 2015: High Adherence and No HIV Infections Seen in Heterosexual PrEP Study in Botswana
- IAS 2015: Pros and Cons of PrEP -- Volunteers Recount their Experiences in ADAPT Study
- IAS 2015: People with Hepatitis B Can Safely Use Truvada PrEP for HIV Prevention
- IAS 2015: Gay Youth PrEP Study Finds Good Retention and Reasonable Adherence
- IAS 2015: U.S. PrEP Demo Project Finds People at Highest HIV Risk Take PrEP Most Consistently
- IAS 2015: Intermittent PrEP May Be Robust Strategy for Anal Sex -- Vaginal Protection Less Certain
- IAS 2015: Non-Daily PrEP Provides Extra Options, But Adherence Often Better with Daily Dosing
- IAS 2015: Gay Men Are Using Nuanced Sero-adaptive Behaviors to Prevent HIV Infection
- IAS 2015: Cash Encourages Circumcision, Prevention of Mother-to-Child HIV Transmission
- IAS 2015: Peer-Led Intervention Lowers HIV Infections Among Drug Injectors in Ukraine
- IAS 2015: Indiana HIV Outbreak -- Lessons about Containing Local Outbreaks and Harm Reduction
- IAS 2015: Vancouver's HIV Treatment as Prevention Success Also Due to Harm Reduction
- IAS 2015: HIV Self-Testing May Help "Hard to Reach" Learn Their Status, but Uncertainties Remain
- IAS 2015: WHO Urges More HIV Testing Outside Clinical Settings, Targeting Those Who Need It Most
- IAS 2015: Many People with Long-term HIV Infection Do Not Achieve Full CD4 Cell Recovery
- IAS 2015: Bone Loss Slows, but Continues Long-term in HIV-positive People on Antiretroviral Therapy
- IAS 2015: HIV+ People with Asymptomatic Cognitive Impairment More Likely to Develop Symptoms
- IAS 2015: Young Gay Men at Lower Risk for HIV than Previous Generations, but Racial Disparities Persist
- IAS 2015: Peer or Community Interventions Improve Outcomes for Mothers with HIV
- Updated Guidelines for Pregnant Women with HIV and Preventing Mother-to-Child Transmission
- IAS 2015: Implant and Injectable Hormonal Contraception Most Effective Methods for Women with HIV
- IAS 2015: Intensification of ART Reduces Risk of Late-term Mother-to-Child HIV Transmission
- IAS 2015: Raltegravir Prevents Mother-to-Child HIV Transmission During Late Pregnancy
- IAS 2015: HIV Treatment Scale-up Linked to Reduced Mortality Among Vancouver Drug Injectors
- IAS 2015: Presumptive Treatment of TB in Advanced HIV No Better than ART and Isoniazid
- IAS 2015: The TPP and Access to HIV and HCV Treatment [VIDEO]
- IAS 2015: Ryan and Julie Lewis -- The 30/30 Project [VIDEO]
- IAS 2015: Vancouver Consensus Calls for Early Access to HIV Treatment and PrEP Worldwide
- IAS 2015: PrEP and the Risk of Hepatitis C Virus Infection [VIDEO]
- IAS 2015: Fibrosis Regression Linked to Reduced Complications and Death in HIV/HCV Coinfected
- IAS 2015: HIV and Hepatitis B Coinfected People Can Safely Switch to Simpler TAF Single-Tablet Regimen
- IAS 2015: Fatty Liver May Contribute to Higher Risk of Death for HIV/HCV Coinfected People
- IAS 2015: Accessing Hepatitis C Treatment [VIDEO]
- IAS 2015: Daclatasvir + Sofosbuvir Cures Most Coinfected People in French Compassionate Use Study
- IAS 2015: Interferon-free Hepatitis Treatment Highly Effective for HIV/HCV Coinfected People
- IAS 2015: Access to Screening and Treatment Are Key Issues for Hepatitis B and C
Web Design and Development by